Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumabChristopher Carlson, Jerome Barakos, Joyce Suhy et al.|Alzheimer s & Dementia|2011Cited by 76
P4‐472: Vasogenic edema in the setting of ß‐amyloid lowering therapy, adverse event: what is it and how is it detected?Jerome Barakos, Eric Siemers, Christopher Carlson et al.|Alzheimer s & Dementia|2011Cited by 3
P4‐089: Prevalence of vasogenic edema and microhemorrhage in an Alzheimer's disease study population at baselineChristopher Carlson, Eric Siemers, Jerome Barakos et al.|Alzheimer s & Dementia|2011Cited by 0